<unk> , sold under the brand name Akynzeo, is a fixed-dose combination medication for prevention of acute and delayed chemotherapy-induced nausea and vomiting. It is marketed and distributed by Helsinn Therapeutics.<unk>  is an NK1 receptor antagonist and<unk>  is a 5-HT3 receptor antagonist. The capsules contain<unk>  and<unk>  hydrochloride. The intravenous version is a combination of fosnetupitant chloride hydrochloride and<unk>  hydrochloride.
Netupitant/palonosetron
Indacaterol/glycopyrronium bromide/mometasone
Ambulatist
Ipratropium bromide/salbutamol
Indacaterol/glycopyrronium bromide
Guaifenesin/phenylephrine
Brinzolamide/brimonidine
Olopatadine/mometasone